Offerings // Lakewood-Amedex Biotherapeutics Inc.

LABT offering history

Every offering-related filing in Lakewood-Amedex Biotherapeutics Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 44 filings back to Jul 31, 2025.

Last executed offering

May 14, 2026

424B4 — priced deal (shares or notes)

Last registration (announced)

Sep 18, 2026

S-1 — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Sep 24, 2026	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Sep 18, 2026	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Aug 17, 2026	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jun 22, 2026	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jun 22, 2026	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
May 26, 2026	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
May 26, 2026	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
May 14, 2026	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
May 13, 2026	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
May 1, 2026	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Apr 30, 2026	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Apr 23, 2026	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Apr 17, 2026	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Apr 6, 2026	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Apr 1, 2026	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Mar 11, 2026	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Feb 13, 2026	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Feb 5, 2026	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Jan 9, 2026	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet

LABT offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes — EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full LABT workspace →

LABT offering FAQ

When did LABT last execute an offering?

Per SEC filings, Lakewood-Amedex Biotherapeutics Inc.'s most recent priced offering document is a 424B4 filed 2026-05-14. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did LABT last announce or register an offering?

The most recent registration is a S-1 filed 2026-09-18. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.

Free to use. No account, no card.